Skip to main content
Equibles
CNBX logo

CNBX · CNBX Pharmaceuticals Inc. · Metrics

Track CNBX — free

Use CNBX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNBX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+0.00%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Jun 24, 2026

Substantial doubt about the company's ability to continue as a going concern.

“While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.”
View the 10-Q filed Jun 24, 2026
Market Cap
$160,576
Shares
1.61B
Volume · Oct 2 500K Avg daily vol (3M) 8.24M

CNBX metrics

46 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$160,576

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
-50.0%
Price change (6M)
+0.0%
Price change (YTD)
-75.0%
Price change (1Y)
-66.7%
Trailing year
Price change (5Y)
—
52-week high
$0.00
52-week low
$0.00
Change from 52-week high
-85.7%
Change from 52-week low
+0.0%
Annualized volatility
584.7%
Annualized volatility (3M)
—
Beta
-0.4
RSI (14D)
47.6
Price vs SMA 50
-19.4%
Price vs SMA 200
-57.1%
Avg volume (3M)
8.24M
Relative volume
0.1
Average dollar volume
$894

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.61B

Valuation

12 metrics
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 1,000.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-287.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$8,130
Operating profit (TTM)
−$429,459
Net income (TTM)
−$462,091
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,995.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-3,611.5%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$9,487
Total assets
$12,795
Total debt
$120,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$154,169
Capital expenditures (TTM)
—
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
$0
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
14 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1343009 CUSIP 13764M209 Visit website Investor relations